Alyeska Investment Group L.P. cut its stake in shares of Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) by 33.6% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 638,943 shares of the company’s stock after selling 322,680 shares during the period. Alyeska Investment Group L.P. owned 1.57% of Pacira Pharmaceuticals worth $23,992,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the business. Oppenheimer Asset Management Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the second quarter worth approximately $114,000. Cubist Systematic Strategies LLC raised its holdings in shares of Pacira Pharmaceuticals by 121.5% in the second quarter. Cubist Systematic Strategies LLC now owns 3,194 shares of the company’s stock worth $152,000 after buying an additional 1,752 shares during the period. QS Investors LLC purchased a new stake in shares of Pacira Pharmaceuticals in the second quarter worth approximately $157,000. Ameritas Investment Partners Inc. raised its holdings in shares of Pacira Pharmaceuticals by 9.6% in the second quarter. Ameritas Investment Partners Inc. now owns 3,449 shares of the company’s stock worth $165,000 after buying an additional 302 shares during the period. Finally, Spectrum Management Group Inc. purchased a new stake in shares of Pacira Pharmaceuticals in the third quarter worth approximately $166,000.

Pacira Pharmaceuticals, Inc. (NASDAQ PCRX) opened at $44.80 on Friday. Pacira Pharmaceuticals, Inc. has a 52 week low of $29.81 and a 52 week high of $58.95. The company has a quick ratio of 6.24, a current ratio of 6.99 and a debt-to-equity ratio of 1.03.

Pacira Pharmaceuticals (NASDAQ:PCRX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.04) by $0.15. Pacira Pharmaceuticals had a negative return on equity of 13.77% and a negative net margin of 18.25%. The company had revenue of $67.30 million for the quarter, compared to analysts’ expectations of $68.99 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. Pacira Pharmaceuticals’s revenue was down 1.6% compared to the same quarter last year. analysts anticipate that Pacira Pharmaceuticals, Inc. will post -0.85 EPS for the current year.

PCRX has been the topic of several recent analyst reports. Canaccord Genuity reduced their price target on Pacira Pharmaceuticals from $56.00 to $48.00 and set a “buy” rating on the stock in a report on Tuesday, August 29th. Mizuho reiterated a “buy” rating and issued a $53.00 price target (down from $54.00) on shares of Pacira Pharmaceuticals in a report on Tuesday, August 22nd. Needham & Company LLC initiated coverage on Pacira Pharmaceuticals in a report on Tuesday, August 22nd. They issued a “buy” rating and a $55.00 price target on the stock. Jefferies Group reiterated a “buy” rating and issued a $59.00 price target on shares of Pacira Pharmaceuticals in a report on Thursday, September 7th. Finally, Zacks Investment Research upgraded Pacira Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a report on Tuesday, October 3rd. Three equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and eight have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $48.86.

In other Pacira Pharmaceuticals news, CAO Kristen Marie Williams sold 10,000 shares of the stock in a transaction on Friday, November 17th. The stock was sold at an average price of $40.00, for a total transaction of $400,000.00. Following the sale, the chief accounting officer now owns 23,455 shares of the company’s stock, valued at approximately $938,200. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Mark A. Kronenfeld bought 1,000 shares of the company’s stock in a transaction on Friday, November 10th. The shares were bought at an average cost of $41.60 per share, for a total transaction of $41,600.00. Following the transaction, the director now directly owns 6,795 shares in the company, valued at approximately $282,672. The disclosure for this purchase can be found here. In the last three months, insiders sold 69,735 shares of company stock worth $2,692,594. 6.60% of the stock is owned by insiders.

COPYRIGHT VIOLATION WARNING: “Alyeska Investment Group L.P. Sells 322,680 Shares of Pacira Pharmaceuticals, Inc. (PCRX)” was published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this story on another site, it was illegally copied and republished in violation of U.S. & international trademark and copyright legislation. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/12/10/alyeska-investment-group-l-p-sells-322680-shares-of-pacira-pharmaceuticals-inc-pcrx.html.

Pacira Pharmaceuticals Company Profile

Pacira Pharmaceuticals, Inc is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers.

Want to see what other hedge funds are holding PCRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX).

Institutional Ownership by Quarter for Pacira Pharmaceuticals (NASDAQ:PCRX)

Receive News & Stock Ratings for Pacira Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacira Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.